Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Spain · Delayed Price · Currency is EUR 54.15
+0.45 (0.84%)
Jul 17, 2026, 5:35 PM CET
BME:ROVI Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 114.76 | 95.94 | 147.72 | 20.22 | 257.97 | 182.63 |
Depreciation & Amortization | 23.1 | 9.6 | 9.41 | 10.23 | 22.87 | 21.36 |
Stock-Based Compensation | - | - | - | - | - | 1.4 |
Other Adjustments | -10.28 | -72.85 | -98.65 | 19.04 | 0.14 | -4.78 |
Change in Receivables | -46 | -2.14 | 6.28 | -29.05 | -26.82 | -74.19 |
Changes in Inventories | 20.58 | 55.71 | -12.25 | 2.93 | -71.59 | -23.43 |
Changes in Accounts Payable | -31.76 | 19.54 | 72.62 | 95.51 | 41.67 | 35.36 |
Changes in Income Taxes Payable | -8.56 | -40.22 | -43.25 | -40.19 | -43.89 | -23.86 |
Changes in Other Operating Activities | -6.37 | 23.45 | 21.45 | 29.71 | 57.26 | 34.94 |
Operating Cash Flow | 95.51 | 44.52 | 51.67 | 54.2 | 237.6 | 149.44 |
Operating Cash Flow Growth | 39.52% | -13.84% | -4.68% | -77.19% | 58.99% | 218.80% |
Capital Expenditures | -36.59 | -8.16 | -3.39 | -5.5 | -50.72 | -40.22 |
Sale of Property, Plant & Equipment | - | 0.18 | 0.02 | 0.1 | 0.08 | 0.03 |
Purchases of Intangible Assets | -1.29 | -0.78 | -2.65 | -0.49 | -0.67 | -0.72 |
Purchases of Investments | - | -52.09 | -32.03 | -8.88 | -5.87 | - |
Proceeds from Sale of Investments | - | 2.54 | 4.06 | 58.71 | 0.02 | - |
Payments for Business Acquisitions | - | -43.14 | -26 | -2.89 | - | - |
Proceeds from Business Divestments | - | 1.8 | 3.77 | 57.93 | - | - |
Other Investing Activities | 0.51 | 0.55 | 0.11 | 0.52 | 0.01 | 0.07 |
Investing Cash Flow | -45.31 | -49.55 | -28.05 | 49.76 | -57.15 | -40.84 |
Long-Term Debt Issued | 1.09 | 218.41 | 215.19 | 12.7 | 1.4 | 1.34 |
Long-Term Debt Repaid | -40.56 | -40.07 | -46.88 | -27.99 | -6.77 | -6.19 |
Net Long-Term Debt Issued (Repaid) | -39.47 | 178.34 | 168.31 | -15.29 | -5.37 | -4.85 |
Issuance of Common Stock | 51.81 | 36.34 | - | - | 77.77 | 42.33 |
Repurchase of Common Stock | -51.6 | -0.02 | -95.57 | -162.52 | -177.01 | -78.79 |
Net Common Stock Issued (Repurchased) | 0.21 | 36.32 | -95.57 | -162.52 | -99.24 | -36.46 |
Common Dividends Paid | - | -95.66 | -112.9 | -138.1 | -51.01 | -21.13 |
Other Financing Activities | 1.49 | 36.34 | - | -0.39 | 1.08 | -0.29 |
Financing Cash Flow | 78.48 | 77.67 | -20.08 | -158.15 | -154.54 | -62.73 |
Net Cash Flow | 69.94 | 72.64 | 3.53 | -54.19 | 25.91 | 45.87 |
Free Cash Flow | 58.92 | 36.36 | 48.28 | 48.7 | 186.88 | 109.22 |
Free Cash Flow Growth | 62.05% | -24.69% | -0.87% | -73.94% | 71.10% | 1348.77% |
FCF Margin | 7.95% | 4.89% | 6.32% | 5.87% | 22.85% | 16.84% |
Free Cash Flow Per Share | 1.15 | 0.71 | 0.94 | 0.92 | 3.50 | 1.97 |
Levered Free Cash Flow | 52.74 | 378.7 | 349.79 | 247.73 | 149.9 | 152.38 |
Unlevered Free Cash Flow | 11.54 | 202.26 | 182.8 | 262.77 | 153.62 | 156.35 |